✦ LIBER ✦

The novel P2Y12 antagonist AZD6140 rapidly and reversibly reduces platelet activation in diabetic rats

✍ Scribed by Ulrike Flierl; Corinna Schöpp; Juliane Jaitner; Johann Bauersachs; Andreas Schäfer

Book ID: 116914249
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 639 KB
Volume: 125
Category: Article
ISSN: 0049-3848
DOI: 10.1016/j.thromres.2009.09.025

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The reversible oral P2Y12 antagonist AZD

The reversible oral P2Y12 antagonist AZD6140 inhibits ADP-induced contractions in murine and human vasculature

✍ Carl Högberg; Helen Svensson; Ronny Gustafsson; Atli Eyjolfsson; David Erlinge 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 408 KB

Inhibition of Platelet Aggregation by AZ

Inhibition of Platelet Aggregation by AZD6140, A Reversible Oral P2Y12 Receptor Antagonist, Compared With Clopidogrel in Patients With Acute Coronary Syndromes

✍ Robert F. Storey; Steen Husted; Robert A. Harrington; Stanley Heptinstall; Rober 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 797 KB

ChemInform Abstract: From ATP to AZD6140

ChemInform Abstract: From ATP to AZD6140: The Discovery of an Orally Active Reversible P2Y12 Receptor Antagonist for the Prevention of Thrombosis.

✍ Brian Springthorpe; et al. et al. 📂 Article 📅 2008 🏛 John Wiley and Sons ⚖ 19 KB 👁 1 views

## Abstract ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable v

Bleeding risk with AZD6140, a reversible

Bleeding risk with AZD6140, a reversible P2Y12 receptor antagonist, vs. clopidogrel in patients undergoing coronary artery bypass grafting in the DISPERSE2 trial

✍ S. Husted; R. A. Harrington; C. P. Cannon; R. F. Storey; P. Mitchell; H. Emanuel 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 148 KB

Impaired Responsiveness to the Platelet

Impaired Responsiveness to the Platelet P2Y12 Receptor Antagonist Clopidogrel in Patients With Type 2 Diabetes and Coronary Artery Disease

✍ Angiolillo, Dominick J.; Jakubowski, Joseph A.; Ferreiro, José Luis; Tello-Monto 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 969 KB

The reversible P2Y12 antagonist cangrelo

The reversible P2Y12 antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function

✍ N. L. DOVLATOVA; J. A. JAKUBOWSKI; A. SUGIDACHI; S. HEPTINSTALL 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 303 KB